Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
A University of Warwick study finds AI cancer detection models may rely on statistical correlations rather than true biomarker signals, raising concerns about reliability in clinical pathology applications.
A Duke-led study reports that measuring piRNAs in blood samples predicts two-year survival in older adults with up to 86% accuracy, outperforming traditional health indicators, according to findings published in Aging Cell.
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
The collaboration will expand access to Alzheimer's biomarker testing through mobile delivery to community centers, churches, and senior centers nationwide.
